**CANCER FUND Invests in NXgenPort to Support Innovative Remote Monitoring of Cancer Patients Undergoing Chemotherapy**

*NXgenPort's Smart Port Technology Aims to* ***Improve Patient Outcomes and Healthcare Costs***

Phoenix, AZ, November 18, 2024 – CANCER FUND announces its investment in NXgenPort, an early-stage company developing technology to advance remote monitoring of cancer patients' health. This marks Cancer Fund I's seventh investment and reflects its dedication to fostering impactful innovations in oncology.

NXgenPort is designing an implantable smart port that integrates vascular access with technology intended to provide real-time, in vivo monitoring of key patient metrics, such as changes in blood cell counts, body temperature and pulse. By utilizing light-scattering technology, NXgenPort's solution seeks to enable continuous data collection that can be synced to a cloud-based dashboard for physician access. This system aims to address gaps in care by supporting earlier detection of potential complications, such as infections, and helping avoid delays in treatment, thus improving outcomes and reducing costs

"We are excited to partner with NXgenPort as they work to bring this promising innovation to life," said Anthony Bajoras, Managing Director of CANCER FUND. "The potential for this technology to improve patient outcomes while reducing healthcare costs aligns strongly with our mission to invest in transformative cancer care."

"Cancer Fund's investment and collaborative approach bring valuable expertise as we continue to develop our smart port technology," said Cathy Skinner, CEO of NXgenPort. "We look forward to working with their team to advance this innovation and improve the standard of care for cancer patients."

**About CANCER FUND:**

CANCER FUND is a community of impact investors committed to advancing cancer care, fostering innovative solutions, and enhancing the lives of cancer patients, survivors, and previvors. Through collaboration with a diverse community nearly 10,000 strong including patients, survivors, caregivers, healthcare professionals, and impact investors, CANCER FUND is currently investing out of Cancer Fund I, LLC, dedicated to driving significant change in the

fight against cancer. To learn more about how you can become part of our investor community, visit www.cancerfund.com.

**About NXgenPort:**

NXgenPort has reimagined the cancer patient experience with a next generation implantable chemo port-catheter utilizing microelectronic sensors that enable the remote management of patients by monitoring and reporting physiological body functions over the course of cancer treatment. NXgenPort is a start-up company raising capital to enable Product Development and expansion of its IP portfolio. More information at https://www.NXgenPort.com.

**Disclaimer**

Contents of this release are provided for general information purposes only and do not constitute an offer to sell or a solicitation of an offer to buy any security of CANCER FUND or its affiliates in any jurisdiction. CANCER FUND does not intend to solicit and IS not soliciting any action with respect to any Security or any other contractual relationship. Nothing in this release or the contents thereof, individually or taken in the aggregate, constitutes an offer of securities for sale or a solicitation of an offer to buy any security in the United States or any other jurisdiction in which such an offer or solicitation is unlawful.

**Forward Looking Statements** When used herein, the words “anticipate", “believe", “could", “estimate", “expect", “going forward”, “intend”, “may”, “ought to”, “plan”, “project”, “seek”, “should”, “will”, “would”, and similar expressions, as they relate to CANCER FUND, CANCER FUND affiliates including Cancer Fund I, LLC, CANCER FUND’s management, or any of their actual or prospective investments, are intended to identify forward-looking statements. These forward-looking statements reflect CANCER FUND’s views at the time such statements were made with respect to future events and are not a guarantee of future performance or developments. You are strongly cautioned that reliance on forward-looking statements involves known,-unknown, and unknowable risks and uncertainties. Actual results and events may differ materially from information contained in the forward-looking statements as a result of a number of factors, including any changes in the laws, rules, and regulations relating to any aspects of CANCER FUND’s or its affiliates’ business operations, general economic, market and business conditions, including capital market developments, changes or volatility in interest rates, foreign exchange rates, equity prices or other rates or prices, various business opportunities that CANCER FUND may or may not pursue, changes in population growth and other demographic

trends, including mortality, morbidity and longevity rates, persistency levels, CANCER FUND's ability to identify, measure, monitor and control risks in CANCER FUND's business, including its ability to manage and adapt its overall risk profile and risk management practices, and seasonal fluctuations and factors beyond CANCER FUND's control. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. CANCER FUND undertakes no obligation to publicly update or revise any forward-looking statements after the date they are made, whether as a result of new information, future events, or otherwise.

**For Media Contact:**

**CANCER FUND**

Email: media@cancerfund.com

Phone: 833-311-3863

**NXgenPort Inc**

Email: cathy@nxgenport.com

Phone: 651-587-5440